Clarithromycin - macrolide antibiotics, semi-synthetic derivative of erythromycin. Unlike erythromycin, changing the molecular structure led to greater bioavailability of clarithromycin, stability in acidic medium, increased concentration in the tissues, expanded antimicrobial spectrum, semi prolonged period of withdrawal, which helped administer the drug twice a day, and thus improve the treatment process. As erythromycin, clarithromycin suppress microbial cell protein synthesis by interacting with ribosomal 50 S subunit of microbial cell membranes. The product is resistant to beta-lactamases microorganisms, in connection with which shows high activity in a relatively wide range of aerobic and anaerobic gram-positive and gram-negative microorganisms.
Clarithromycin is active against most strains of the following microorganisms:
Gram-positive aerobes - Staphylococcus aureus, Streptococcus agalactiae (pyogenes, viridans, pneumoniae), Listeria monocytogenes, Corynebacterium spp .;
aeroby- Gram Haemophilus influenzae (parainfluenzae), Neisseria gonorrhoeae, Helicobacter pylori, Legionella pneumophila, Moraxella catarrhalis;
mycobacteria - Mycobacterium leprae, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium cansasii, complex Mycobacterium avium, which includes Mycobacterium avium i Mycobacterium intracellulare;
Other micro-organisms - Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia trachomatis, Ureaplasma urealyticum, Toxop